For Novavax, Building Trust Was Key To Improving Diversity

Company Took Lead In Native American Vaccine Study Enrollment

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
Novavax relied on building trust to increase diversity in its COVID-19 vaccine trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Diversity & Inclusion

More from ESG